Table 3.
Brain imaging analysis.
| Total | LGS with MRC I deficiency | LGS without MRC I deficiency | p-value | |
|---|---|---|---|---|
| (n = 68) | (n = 30) | (n = 38) | ||
| Brain MRI lesion | ||||
| Basal ganglia | 6 (8.8) | 4 (13.3) | 2 (5.3) | 0.394 |
| Thalamus | 6 (8.8) | 5 (16.7) | 1 (2.6) | 0.080 |
| Midbrain | 3 (4.4) | 2 (6.7) | 1 (2.6) | 0.579 |
| Pons | 1 (1.5) | 1 (3.3) | 0 | 0.441 |
| Medulla | 1 (1.5) | 1 (3.3) | 0 | 0.441 |
| Cerebral cortex | 9 (13.2) | 3 (10.0) | 6 (15.8) | 0.721 |
| White matter | 30 (44.1) | 15 (50.0) | 15 (39.5) | 0.464 |
| Cerebellum | 13 (19.1) | 8 (26.7) | 5 (13.2) | 0.217 |
| Atrophy | 41 (60.3) | 24 (80.0) | 17 (44.7) | 0.006 |
| Brain MRS findings | ||||
| Lactate peak (+) | 5 (7.4) | 5 (16.7) | 0 | 0.014 |
| Decreased NAA peak (+) | 30 (44.1) | 23 (76.7) | 7 (18.4) | < 0.001 |
The data are presented as n (%).
LGS, Lennox–Gastaut syndrome; MRC I, mitochondrial respiratory chain complex I; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAA, N-acetylaspartate.